Thora Y Chai1, Katherine T Tonks2, Lesley V Campbell3. 1. School of Medicine Sydney, University of Notre Dame Australia, Darlinghurst, NSW, Australia. 2. Department of Endocrinology, St. Vincent's Hospital Sydney, Darlinghurst, NSW, Australia. 3. Diabetes and Metabolism Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Abstract
BACKGROUND: Diabetic patients are commonly hyperglycaemic on presentation. Admission hyperglycaemia is associated with adverse outcomes, particularly prolonged hospitalisation. Improving inpatient glycaemia may reduce length of hospital stay (LOS) in diabetic patients. AIMS: To determine whether in-hospital recognition and treatment of admission hyperglycaemia in diabetic patients is associated with reduced LOS. METHODS: Medical records were reviewed from 1 November 2011 to 31 May 2012 for 162 diabetic patients admitted with a blood glucose level (BGL) ≥11.1mmol/L. In-hospital outcomes were compared. Stepwise multiple regression was used to evaluate factors contributing to LOS. RESULTS: Compared to the untreated individuals (n=67), hyperglycaemia treatment (n=95) was associated with a longer LOS (median eight vs. four days, p<0.01), higher HbA1c (9.0 vs. 7.3 per cent, p<0.01), more infections (50 vs. 25 per cent, p<0.01), and more patients with follow-up plans (35 vs. 10 per cent, p<0.01). Higher HbA1c was significantly related to more follow-up (ρs=0.30, n=110, p<0.01) with a trend to lower re-admission in those with follow-up plans (ρs=-1.41, n=162, p=0.07). CONCLUSION: Recognition and treatment of admission hyperglycaemia in diabetic patients was associated with longer LOS than if untreated. Contributory factors to LOS include: illness severity, infections, and higher HbA1c. Although follow-up plans were few (27 per cent) for diabetic patients with hyperglycaemia, it was significantly more likely in those with higher HbA1c. Diabetic patients' complexities require timely multidisciplinary team involvement. Improved follow-up care, particularly for hospitalised diabetic patients identified to have chronically poor glycaemic control, may help prevent future diabetic patient re-admissions.
BACKGROUND:Diabeticpatients are commonly hyperglycaemic on presentation. Admission hyperglycaemia is associated with adverse outcomes, particularly prolonged hospitalisation. Improving inpatient glycaemia may reduce length of hospital stay (LOS) in diabeticpatients. AIMS: To determine whether in-hospital recognition and treatment of admission hyperglycaemia in diabeticpatients is associated with reduced LOS. METHODS: Medical records were reviewed from 1 November 2011 to 31 May 2012 for 162 diabeticpatients admitted with a blood glucose level (BGL) ≥11.1mmol/L. In-hospital outcomes were compared. Stepwise multiple regression was used to evaluate factors contributing to LOS. RESULTS: Compared to the untreated individuals (n=67), hyperglycaemia treatment (n=95) was associated with a longer LOS (median eight vs. four days, p<0.01), higher HbA1c (9.0 vs. 7.3 per cent, p<0.01), more infections (50 vs. 25 per cent, p<0.01), and more patients with follow-up plans (35 vs. 10 per cent, p<0.01). Higher HbA1c was significantly related to more follow-up (ρs=0.30, n=110, p<0.01) with a trend to lower re-admission in those with follow-up plans (ρs=-1.41, n=162, p=0.07). CONCLUSION: Recognition and treatment of admission hyperglycaemia in diabeticpatients was associated with longer LOS than if untreated. Contributory factors to LOS include: illness severity, infections, and higher HbA1c. Although follow-up plans were few (27 per cent) for diabeticpatients with hyperglycaemia, it was significantly more likely in those with higher HbA1c. Diabeticpatients' complexities require timely multidisciplinary team involvement. Improved follow-up care, particularly for hospitalised diabeticpatients identified to have chronically poor glycaemic control, may help prevent future diabeticpatient re-admissions.
Entities:
Keywords:
community management; diabetes mellitus; glycaemic control; hyperglycaemia
Authors: Anthony P Furnary; Guangqiang Gao; Gary L Grunkemeier; YingXing Wu; Kathryn J Zerr; Stephen O Bookin; H Storm Floten; Albert Starr Journal: J Thorac Cardiovasc Surg Date: 2003-05 Impact factor: 5.209
Authors: William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang Journal: N Engl J Med Date: 2008-12-17 Impact factor: 91.245
Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2012-04-19 Impact factor: 19.112
Authors: Duncan Macrae; Richard Grieve; Elizabeth Allen; Zia Sadique; Kevin Morris; John Pappachan; Roger Parslow; Robert C Tasker; Diana Elbourne Journal: N Engl J Med Date: 2014-01-09 Impact factor: 91.245